Volume 60, Issue 6, Pages 2406-2411 (December 2001) A randomized trial of iron deficiency testing strategies in hemodialysis patients1  Steven Fishbane, M.D., Warren Shapiro, Paula Dutka, Osvaldo F. Valenzuela, Jessy Faubert  Kidney International  Volume 60, Issue 6, Pages 2406-2411 (December 2001) DOI: 10.1046/j.1523-1755.2001.00077.x Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 1 Intravenous iron dextran weekly dose requirements by study group. (Reproduction of this figure in color was made possible by Bayer Diagnostics, Inc.) Kidney International 2001 60, 2406-2411DOI: (10.1046/j.1523-1755.2001.00077.x) Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 2 Distribution of reticulocyte hemoglobin content (CHr) values among all subjects. (Reproduction of this figure in color was made possible by Bayer Diagnostics, Inc.) Kidney International 2001 60, 2406-2411DOI: (10.1046/j.1523-1755.2001.00077.x) Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 3 Histograms of reticulocyte hemoglobin content (CHr). Results are from a single patient at baseline, and then 2 and 4 weeks after intravenous iron treatment. As hematocrit (Hct) and CHr improve, the population of reticulocytes matures and normalizes compared to mature cells. (Reproduction of this figure in color was made possible by Bayer Diagnostics, Inc.) Kidney International 2001 60, 2406-2411DOI: (10.1046/j.1523-1755.2001.00077.x) Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 4 Coefficient of variation (CV) for the three tests. Blue bars represent all tests, purple bars represent CV excluding tests performed after intravenous iron treatment. (Reproduction of this figure in color was made possible by Bayer Diagnostics, Inc.) Kidney International 2001 60, 2406-2411DOI: (10.1046/j.1523-1755.2001.00077.x) Copyright © 2001 International Society of Nephrology Terms and Conditions